Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Aug 4, 2010
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects must have experienced a myocardial infarction (STEMI) within the previous 24 hours confirmed by symptoms and ECG.
- Exclusion Criteria:
- • Subjects with a known low ejection fraction of less than 40% or any previous history of heart failure.
- • Subjects treated with eplerenone or other aldosterone antagonists within the past 1 month.
- • The subject has uncontrolled hypotension (SBP\<90mmHg).
- • Subjects with eGFR ≤30ml/min (based on admission serum creatinine and the MDRD formula) or serum creatinine ≥220µmol/L.
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edmonton, Alberta, Canada
Toronto, Ontario, Canada
Creteil, , France
Hannover, , Germany
Toronto, Ontario, Canada
Valencia, , Spain
Birmingham, , United Kingdom
Dundee, , United Kingdom
Chicoutimi, Quebec, Canada
Martin, , Slovakia
Madrid, , Spain
Limburg, , Germany
Bonn, , Germany
Nieuwegein, , Netherlands
Rimavska Sobota, , Slovakia
Coventry, , United Kingdom
Hradec Kralove, , Czechia
Brno, , Czechia
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
Vancouver, British Columbia, Canada
Vancouver, British Columbia, Canada
St. John's, Newfoundland And Labrador, Canada
Chicoutimi, Quebec, Canada
Sherbrooke, Quebec, Canada
Olomouc, , Czechia
Olomouc, , Czechia
Praha 4, , Czechia
Praha 5, , Czechia
Toulouse, Cedex 4, France
Dijon, Cedex, France
Paris, Cedex, France
Cannes, , France
Creteil, , France
Evecquemont, , France
Libourne, , France
Pessac Cedex, , France
Bad Krozingen, , Germany
Berlin, , Germany
Bremen, , Germany
Dortmund, , Germany
Dortmund, , Germany
Dresden, , Germany
Goettingen, , Germany
Hamburg, , Germany
Mainz, , Germany
Munich, , Germany
Athens, , Greece
Athens, , Greece
Rio Patra, , Greece
Budapest, , Hungary
Gyor, , Hungary
Nyiregyhaza, , Hungary
Zalaegerszeg, , Hungary
Amsterdam, , Netherlands
Bydgoszcz, , Poland
Olsztyn, , Poland
Oswiecim, , Poland
Wroclaw, , Poland
Banska Bystrica, , Slovakia
Bratislava, , Slovakia
Nitra, , Slovakia
Jerez De La Frontera, Cadiz, Spain
Barcelona, , Spain
Barcelona, , Spain
Madrid, , Spain
Palma De Mallorca, , Spain
Blackpool, Lancashire, United Kingdom
Edinburgh, Lothian, United Kingdom
Swansea, Wales, United Kingdom
Cottingham Hull, , United Kingdom
Edinburgh, , United Kingdom
Leicester, , United Kingdom
Swansea, , United Kingdom
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials